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Abstract
Introduction: Cartilage degeneration driven by catabolic stimuli is a critical pathophysiological process in
osteoarthritis (OA). We have defined fibroblast growth factor 2 (FGF-2) as a degenerative mediator in adult human
articular chondrocytes. Biological effects mediated by FGF-2 include inhibition of proteoglycan production, up-
regulation of matrix metalloproteinase-13 (MMP-13), and stimulation of other catabolic factors. In this study, we
identified the specific receptor responsible for the catabolic functions of FGF-2, and established a
pathophysiological connection between the FGF-2 receptor and OA.
Methods: Primary human articular chondrocytes were cultured in monolayer (24 hours) or alginate beads (21
days), and stimulated with FGF-2 or FGF18, in the presence or absence of FGFR1 (FGF receptor 1) inhibitor.
Proteoglycan accumulation and chondrocyte proliferation were assessed by dimethylmethylene blue (DMMB) assay
and DNA assay, respectively. Expression of FGFRs (FGFR1 to FGFR4) was assessed by flow cytometry,
immunoblotting, and quantitative real-time PCR (qPCR). The distinctive roles of FGFR1 and FGFR3 after stimulation
with FGF-2 were evaluated using either pharmacological inhibitors or FGFR small interfering RNA (siRNA). Luciferase
reporter gene assays were used to quantify the effects of FGF-2 and FGFR1 inhibitor on MMP-13 promoter activity.
Results: Chondrocyte proliferation was significantly enhanced in the presence of FGF-2 stimulation, which was
inhibited by the pharmacological inhibitor of FGFR1. Proteoglycan accumulation was reduced by 50% in the
presence of FGF-2, and this reduction was successfully rescued by FGFR1 inhibitor. FGFR1 inhibitors also fully
reversed the up-regulation of MMP-13 expression and promoter activity stimulated by FGF-2. Blockade of FGFR1
signaling by either chemical inhibitors or siRNA targeting FGFR1 rather than FGFR3 abrogated the up-regulation of
matrix metalloproteinases 13 (MMP-13) and a disintegrin and metalloproteinase with a thrombospondin type 1
motif 5 (ADAMTS5), as well as down-regulation of aggrecan after FGF-2 stimulation. Flow cytometry, qPCR and
immunoblotting analyses suggested that FGFR1 and FGFR3 were the major FGFR isoforms expressed in human
articular chondrocytes. FGFR1 was activated more potently than FGFR3 upon FGF-2 stimulation. In osteoarthritic
chondrocytes, FGFR3 was significantly down regulated (P < 0.05) with a concomitant increase in the FGFR1 to
FGFR3 expression ratio (P < 0.05), compared to normal chondrocytes. Our results also demonstrate that FGFR3 was
negatively regulated by FGF-2 at the transcriptional level through the FGFR1-ERK (extracellular signal-regulated
kinase) signaling pathway in human articular chondrocytes.
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any medium, provided the original work is properly cited.Conclusions: FGFR1 is the major mediator with the degenerative potential in the presence of FGF-2 in human
adult articular chondrocytes. FGFR1 activation by FGF-2 promotes catabolism and impedes anabolism. Disruption of
the balance between FGFR1 and FGFR3 signaling ratio may contribute to the pathophysiology of OA.
Introduction
Osteoarthritis (OA) is a debilitating disease afflicting
millions of people worldwide, which imposes a tremen-
dous burden upon society. OA is a multifactorial hetero-
geneous disease that is influenced by both genetic and
environmental factors [1]. A wide array of enzymes,
such as matrix metalloproteinases (MMPs) and a disin-
tegrin and metalloproteinase with a thrombospondin
type 1 motif (ADAMTS), and pro-inflammatory cyto-
kines, have been implicated in pathological processes
associated with OA, such as cartilage degradation, syno-
vial inflammation and bone abnormalities [2]. Notably,
the products of cartilage degeneration not only further
promote matrix degradation, but also stimulate the
synovium to overproduce inflammatory mediators and
degrading proteases, which, in turn, exacerbate cartilage
matrix loss [2]. Such autocrine and paracrine loops per-
petuate joint destruction, frequently resulting in irrever-
sible disease progression.
Progressive damage to articular cartilage is a hallmark
of OA, and a principal cause of tissue break-down is the
destruction rather than formation of the cartilage extra-
cellular matrix by chondrocytes. Thus, metabolic home-
ostasis is perturbed at the cellular level in OA because
chondrocyte catabolism predominates over anabolism
resulting in net cartilage degeneration. Elevated levels of
pro-inflammatory cytokines, inflammatory mediators
and certain growth factors potently heighten the expres-
sion of matrix-degrading enzymes. Destructive proteases
such as MMP-13 and ADAMTS-5 are able to cleave
major components in the extracellular matrix of chon-
drocytes, including type II collagen and aggrecan [3,4].
In response to tissue damage, chondrocytes make
attempts at matrix repair, but they often fail to restore
the eroded cartilage to its original pristine hyaline state,
due to multiple impairing mechanisms [5-8].
FGF-2 participates in the regulation of cartilage home-
ostasis in addition to its well-established mitogenic role
[9]. Released from the extracellular matrix upon tissue
injury [10], FGF-2 stimulates MMP-13 expression,
which may accelerate cartilage degradation [11]. In both
articular chondrocytes and meniscal chondrocytes, FGF-
2 alters the ratio between type II and type I collagen,
thus possibly resulting in the formation of fibrocartilage,
a defective substitute for healthy hyaline cartilage
[12,13]. In porcine articular chondrocytes, FGF-2 antag-
onizes IGF-1/TGF-b-mediated type II collagen and dec-
orin production [14]. Moreover, FGF-2 potently inhibits
IGF-1/BMP-7-enhanced proteoglycan accumulation and
synthesis in human articular chondrocytes, even though
it stimulates proliferation, and markedly affects physical
properties of normal cartilage [5,15]. Recent studies by
others, suggest a chondroprotective role of FGF-2 in
cartilage biology, which merits additional studies to
resolve the physiological complexities linked to the
opposing biological functions of FGF-2 in human articu-
lar cartilage [16,17].
Our group has clearly established that FGF-2 exerts
catabolic effects in primary human articular chondro-
cytes cultured ex vivo, thus mechanistically predicting
cartilage degradation in human patients. Previously, we
showed that FGF-2 inhibits the synergistic anabolic
effects of IGF-1 and BMP-7, and also stimulates MMP-
13 expression via protein kinase C δ (PKCδ)-mediated
activation of multiple MAP kinases (ERK1/2, p38 and
JNK) [5,18]. We also showed that FGF-2 activates the
NFB pathway, which converges with the MAP kinase
pathway on the activation of transcription factor Elk-1
to stimulate MMP-13 transcription [19].
There are four different isoforms of FGF receptors
(FGFR1 to FGFR4) that are responsible for the biological
impact of FGF-2 through the developmental stages [20].
It is still not clear which receptor(s) mediate the cata-
bolic and/or anti-anabolic signaling by FGF-2 as we pre-
viously observed, and what other target genes than
MMP-13 are regulated by FGF-2 in human adult articu-
lar cartilage [5,18,19]. In this study, we examined which
of the main FGFR isoforms mediate the biological
effects of FGF-2, characterized critical FGF-2-regulated
genes that depend on FGF-2/receptor signaling. We also
determined the potential pathological alterations in the
expression profiles of FGFR isoforms by comparing car-
tilage from healthy (Collin’ grade 0 or 1) and age- and
gender-matched osteoarthritic knee joints (surgically
removed).
Materials and methods
Materials
Human recombinant FGF-2 was purchased from the
National Cancer Institute (Bethesda, MD, USA). Human
recombinant FGF18 was purchased from PeproTech
(Rocky Hill, NJ, USA). Antibodies against human Flg
(FGFR1), Bek (FGFR2), FGFR3, FGFR4, and phospho-
Tyrosine (PY99) were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). The antibody against
human b-actin was purchased from Abcam (Cambridge,
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was purchased from Millipore (Billerica, MA, USA) and
the antibody against MMP-13 and FGFR1 neutralizing
a n t i b o d yw e r ep r o v i d e db yc o u r t e s yo fD r .G i l l i a nM u r -
phy and Dr. Simon Cool, respectively. The MMP-13
antibody was described previously [21]. A full character-
ization of the neutralizing antibody against FGFR1 is
provided elsewhere [22]. The titer of the latter antibody
is equal or higher than 1:200,000 as determined by stan-
dard enzyme-linked immunosorbent assay (ELISA).
Pharmacological inhibitor SU5402 (FGFR1i) and
PD98059 (ERKi) were purchased from Calbiochem/
EMD Chemicals (Gibbstown, NJ, USA). The SU5402
concentrations used in this study (5 μM and 2 μM) did
not lead to significant inhibition of FGFR3 phosphoryla-
tion, as determined by immunoprecipitation and immu-
noblotting (data not shown). Stealth small interfering
RNA (siRNA) targeting FGFR1 and FGFR3 were pur-
chased from Invitrogen (Carlsbad, CA, USA).
Chondrocyte isolation and culture
Normal human knee cartilage tissues were obtained
within 24 hours of death of donors (age ranging from
40 to 65) from the Gift of Hope Organ and Tissue
Donor Network (Elmhurst, IL, USA) with approval by
the local ethics committee and consent from the
families. Prior to dissection, each specimen was graded
for overall degenerative changes based on the modified
5-point scale of Collins [23]. Surgically removed carti-
lage from OA patients (age ranging from 40 to 65) were
obtained from the Orthopedic Tissue and Implant Repo-
sitory Study with consent from the patients. Human tis-
sues were handled according to the guidelines of the
Human Investigation Committee of Rush University
Medical Center.
Chondrocytes were isolated by enzymatic digestion of
cartilage using Pronase for one hour, followed by over-
night digestion with collagenase-P as described pre-
viously [5,24]. For monolayer cultures, isolated cells
were washed and suspended in culture media at 3 × 10
6
cells/mL, and seeded onto 12-well plates using 1 mL
media/well. Cells were maintained in Dulbecco’sM o d i -
fied Eagle’s Medium (DMEM)/F-12 (1:1) containing 10%
fetal bovine serum and antibiotics (complete media) for
three days before the treatments. For alginate bead cul-
ture, cells were suspended in alginate (2 × 10
6 cells/mL)
immediately after enzymatic digestion and washing
steps, and beads were formed in CaCl2 solution, as
described previously [25,26]. Beads were cultured in
DMEM/F-12 medium (1:1), supplemented with 1%
mini-ITS+ premix and 0.1% ascorbic acid, at eight beads
per well in 24-well plates. Chondrocytes used for profil-
ing FGFR isoform expression were processed immedi-
ately after cell isolation from cartilage.
Chondrocyte stimulation and immunoblotting
Prior to treatments, chondrocytes were growth factor
deprived in serum-free DMEM/F-12 (1:1) for 24 hours.
Media were replaced again with fresh serum-free
DMEM/F-12 (1:1) two hours before stimulation. When
inhibitors were applied, cells were pre-incubated with
individual pathway-specific inhibitors for one hour
before stimulation with FGF-2 (100 ng/mL). After termi-
nating the experiments, conditioned media and whole
cell lysates were collected. Media were stored at 4°C
with 0.1% NaN3, and used within five days. Cell lysates
were prepared using modified cell lysis RIPA buffer: 20
mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Nonidet P-40, 0.25% deoxycholate, 2.5 mM
sodium pyrophosphate, 1 mM glycerol phosphate, 1
mM NaVO4, and 2 mM phenylmethylsulfonyl fluoride
(Sigma, St Louis, MO, USA). Total protein concentra-
tions of the cell lysates were determined using the
bicinchoninic acid (BCA) assay (Thermo Scientific,
Rockford, IL, USA). Equal amounts of protein were
resolved in 10% SDS-polyacrylamide gels and transferred
to nitrocellulose membrane for immunoblotting analyses
as described previously [24]. Immunoreactivity was
visualized using an ECL system (Pierce, Rockford, IL,
USA).
Immunoprecipitation
Whole cell lysates were prepared as described above and
centrifuged at 12,500 rpm for 20 minutes. Supernatants
were transferred and incubated with antibody against
FGFR1 or FGFR3 immobilized to Protein A agarose
beads (Thermo Scientific, Rockford, IL, USA). Beads
were maintained in homogenous suspension overnight
at 4°C using a rotary wheel that supports ‘end-over-end’
mixing. Beads were then washed three times with bind-
ing buffer (0.14 M NaCl, 0.008 M sodium phosphate,
0.002 M potassium phosphate, 0.01 M KCl, pH 7.4).
The samples were eluted and subjected to SDS-PAGE.
Total RNA extraction, cDNA synthesis, and quantitative
real-time PCR
Total RNA from normal and osteoarthritic human
articular chondrocytes was isolated using Trizol reagent
(Invitrogen, Carlsbad, CA, USA) following the instruc-
tions provided by the manufacturer. Reverse transcrip-
tion (RT) was carried out with 1 μgt o t a lR N Au s i n g
ThermoScript
TM RT-PCR system (Invitrogen) for first
strand cDNA synthesis. For real-time PCR, cDNA was
amplified using MyiQ Real-Time PCR Detection System
(Bio-Rad, Hercules, CA, USA). Relative gene expression
was determined using the
ΔΔCT method, using detailed
guidelines provided by the manufacturer (Bio-Rad). 18S
rRNA and GAPDH were used as internal controls for
normalization. The standard deviations in samples were
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in independent experiments. The primer sequences are
summarized in Table 1.
Dimethylmethylene blue (DMMB) assay and DNA assay
Cultured cells on alginate beads were collected and pro-
cessed for quantitative assays using the DMMB binding
method, as previously described [26,27]. The pH of
DMMB solution used in this study was 1.5, in order to
minimize the interfering effect of alginate, as previously
demonstrated [28]. The proteoglycan levels in the cell-
associated matrix were measured. Cell viability and cell
numbers were determined using PicoGreen (Invitrogen),
as previously described [26].
Transient transfection
Nucleofection was optimized for human articular chon-
drocytes based on the manual of the Nucleofector
™ kit
(Lonza, Walkersville, MD, USA) as described previously
[29,30]. Chondrocytes were cultivated for three days
before transfection. For FGFR knockdown experiments,
siRNA at a concentration of 200 nM (20 pmol/sample)
was used during transfection. After 48 hours, cell lysates
were subjected to SDS-PAGE and immunoblotting for
validation of successful knockdown. In parallel, stimula-
tions were performed 48 hours after the transfection. In
promoter activity assays, as internal control for transfec-
tion efficiency, the Renilla Luciferase vector (pRL-TK)
was co-transfected with the MMP-13 promoter/firefly
luciferase constructs as we described previously [18].
Both Renilla and firefly luciferase activity were measured
simultaneously using a dual-luciferase reporter assay
system (Promega, Madison, WI, USA) and a lumin-
ometer (Berthold, Huntsville, AL, USA).
Flow cytometry analysis
Immunofluorescence labeling of FGFRs was performed as
previously described [31]. Human articular chondrocytes
were incubated with anti-CD32/CD16 monoclonal anti-
body to block Fc receptor-mediated nonspecific antibody
binding. Primary antibodies against FGFR1, FGFR2,
FGFR3, and FGFR4 were incubated with cells, followed by
addition of secondary antibody, goat-anti-rabbit Alexa
Fluor 488 (Invitrogen). Cells were also incubated with goat-
anti-rabbit Alexa Fluor 488, or non-immune rabbit serum
plus goat-anti-rabbit Alexa Fluor 488 as controls. FGFRs
present on the plasma membrane of chondrocytes were
analyzed using a FACS Calibur instrument and CellQuest
software (BD Flow Cytometry Systems, San Jose, CA, USA).
Statistical analysis
Statistical significance was determined by Student’s t-
test, or one-way repeated measures ANOVA followed
by Sidak post-hoc test using the SPSS 17 program. P-
values lower than 0.05 were considered to be statistically
significant in each test.
Results
FGF-2-mediated cellular proliferation and proteoglycan
loss is via FGFR1 in human articular chondrocytes
Previously, we reported FGF-2-mediated cell proliferation
and significant proteoglycan loss in human articular carti-
lage using in vitro and ex vivo explant culture systems [5].
Dynamic interactions of FGF-2 with its cognate receptors,
FGFR1 and FGFR3 were shown to elicit distinctive biologi-
cal responses. FGF-2 binds to all FGFR isoforms, yet with
higher affinity to FGFR1 and FGFR3 [32]. We investigated
which specific FGFR isoforms are responsible for the FGF-
2-mediated cellular proliferation and proteoglycan loss.
Human articular chondrocytes in alginate beads were
incubated with FGF-2 for 21 days in the presence or
absence of a pharmacological inhibitor that blocks the tyro-
sine kinase activity of FGFR1 (SU5402, 2 μM) or a
Table 1 Real-time PCR primer sequences
Gene Primer Sequence (5’®3’) NCBI Gene
Number
Anneal
Tm
MMP13 F:
ACCCTGGAGCACTCATGTTTCCTA
R:
TGGCATCAAGGGATAAGGAAGGGT
NM_002427.3 60°C
ADAMTS5 F:
CTGTGACGGCATCATTGGCTCAAA
R:
TTCAGGAATCCTCACCACGTCAGT
NM_007038.3 60°C
ACAN F:
TCTTGGAGAAGGGAGTCCAACTCT
R:
ACAGCTGCAGTGATGACCCTCAGA
NM_001135.3 60°C
FGFR1 F:
AACCTGACCACAGAATTGGAGGCT
R:
ATGCTGCCGTACTCATTCTCCACA
NM_023110.2 60°C
FGFR2 F:
TGATGGACTTCCTTATGTCCGCGT
R:
AGCGTCCTCTTCTGTGACATTGGT
NM_000141.4 60°C
FGFR3 F:
ACCAATGTGTCTTTCGAGGATGCG
R:
AGAGCACGCAGCTTGTCACATAGA
NM_000142.4 60°C
FGFR4 F:
ATGGAACTGGTGTGCTCAAGAAGC
R:
TTCACATGTCCTCCGACCAACACA
NM_002011.3 60°C
18S rRNA F: CGGCTACCACATCCAAGGAA
R: GCTGGAATTACCGCGGCT
NR_003286.2 60°C
GAPDH F:
TCGACAGTCAGCCGCATCTTCTTT
R:
GCCCAATACGACCAAATCCGTTGA
NM_002046.3 60°C
ACAN, aggrecan core protein; ADAMTS5, a disintegrin and metalloproteinase
with a thrombospondin type 1 motif 5; FGFR, fibroblast growth factor
receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MMP13, matrix
metalloproteinase-13.
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Treatment with FGF18 was included in parallel, because its
pro-anabolic activity for matrix formation is exclusively
mediated through activation of FGFR3 in human articular
cartilage [33]. Accumulated cell-associated proteoglycan
and cellular proliferation were assessed by DMMB assay.
Our results show that FGF-2 significantly reduced proteo-
glycan production, whereas FGF18 was pro-anabolic (Fig-
ure 1A), consistent with previous findings [5,33,34]. In
parallel, we found that FGF-2 but not FGF18 significantly
induced cell proliferation (up to two-fold) (Figure 1B). This
reduction of proteoglycan biosynthesis and stimulation of
proliferation by FGF-2 were each completely abolished by
co-incubation with either the pharmacological inhibitor of
FGFR1 (2 μM) or the neutralizing anti-FGFR1 antibody,
while neither agent affected FGF18-mediated proteoglycan
production (Figure 1A, B). Consistent with our previous
report, FGF-2 did not alter cell survival, suggesting FGF-2
does not impact cell death (data not shown) [5]. These
data indicate that the biological impact of FGF-2 is
achieved via the activation of FGFR1 but not FGFR3. Our
data corroborate the current concept that FGFR1 and
FGFR3 have distinct biological roles in articular chondro-
cytes, and that activation of FGFR3 by FGF18 is anabolic
for human articular cartilage homeostasis [33,34].
FGFR1 is responsible for the up-regulation of MMP-13
and ADAMTS5, as well as down-regulation of aggrecan
by FGF-2 in human articular chondrocytes
We examined whether FGFR1 is the major receptor
responsible for FGF-2-dependent regulation of genes
encoding cartilage-degrading enzymes (for example,
MMP-13 and ADAMTS5), or major cartilage-related
proteoglycans (for example, aggrecan). Because we were
interested in investigating the FGFR1-altered transcrip-
tional regulation of the target gene that requires 24-
hour incubation, we utilized a monolayer culture system
instead of a long-term alginate bead culture system.
Human chondrocytes in monolayer were pre-incubated
with either SU5402 (5 µM), a pharmacological inhibitor
that blocks the tyrosine kinase activity of FGFR1, or a
neutralizing antibody directed against FGFR1 (lane 3
and 4) followed by stimulation with FGF-2 (100 ng/mL)
for 24 hours. Based on a previous report, the SU5402
inhibitor has an IC50 of 10 to 20 μM for FGFR1 inhibi-
tion [35]. Our empirically determined SU5402 concen-
tration (5 μM) differs from the reported IC50,w h i c h
may be attributed to differences in biological context,
experimental conditions and readouts. Conditioned
m e d i aw e r ec o l l e c t e df o ra n a l y s e so fM M P - 1 3a n d
ADAMTS5 mRNA levels using RT-qPCR with human-
specific primer sets for MMP13 and ADAMTS5 that
had been validated in our laboratory [36]. Stimulation of
cells with FGF-2 alone significantly induced MMP-13
(Figure 2A; P < 0.05) and ADAMTS5 (Figure 2B; P <
0.05) at both mRNA and protein levels. The biological
modulations of FGF-2 on MMP13 and ADAMTS5 were
abolished in the presence of either the FGFR1 inhibitor
(P < 0.05) or the FGFR1 neutralizing antibody (P <
0.05). By clear contrast, FGF18 (100 ng/mL), which spe-
cifically activates FGFR3, failed to stimulate catabolic
enzyme production, and its action was not altered by
Figure 1 The effect of FGF-2 on proteoglycan accumulation and cell proliferation. Human articular chondrocytes were cultured in alginate
beads with indicated treatments for 21 days before assaying for proteoglycan and DNA content. (A) Proteoglycan accumulation was assessed
by dimethylmethylene blue (DMMB) assay, normalized by DNA content. (B) Cellular proliferation was quantified by total DNA content in beads
from each treatment group. * P < 0.05; ** P < 0.01. FGF, fibroblast growth factor.
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Page 5 of 13Figure 2 Effects mediated by FGFR1 upon FGF-2 binding. ( A ,B ,E )Human articular chondrocytes in monolayer were treated with FGF-2
(100 ng/mL), in the absence or presence of FGFR1 neutralization antibody (1:1,000, 1:200) or SU5402 (5 μM), for 24 hours. In parallel,
chondrocytes were transfected with siRNA targeting FGFR1 or FGFR3, and subjected to 24-hour FGF-2 (100 ng/mL) stimulation. Conditioned
media were collected for immunoblotting analyses of matrix metalloproteinase-13 (MMP-13) and a disintegrin and metalloproteinase with a
thrombospondin type 1 motif 5 (ADAMTS5). Total RNA was extracted for cDNA synthesis and qPCR quantification of gene expression. * P < 0.05.
(C) Chondrocyte lysates were prepared 48 hours after siRNA transfection. The samples were resolved by SDS-PAGE, and immunoblotted for
FGFR1 and FGFR3 protein expression. GAPDH was used as a loading control. (D) -1600MMP-13 Luciferase-promoter construct was transiently
transfected into human articular chondrocytes. The transfected cells were pre-incubated with neutralizing antibody (1:1,000, 1:200) or 5 μM
SU5402 for 1 hour, and then stimulated with FGF-2 (100 ng/mL) for 24 hours. The luciferase activity representing MMP-13 promoter activity was
measured. A Renilla vector was co-transfected as an internal control for normalization. * P < 0.05. ADAMTS, a disintegrin and metalloproteinase
with a thrombospondin type 1 motif; FGF, fibroblast growth factor; FGFR, FGF receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
MMP, matrix metalloproteinase; qPCR, quantative polymerase chain reaction; siRNA, small interfering RNA.
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shown).
To substantiate our findings, human articular chon-
drocytes in monolayer were transfected with either
FGFR1-specific or FGFR3-specific siRNA. Cells were
then stimulated with FGF-2 (100 ng/mL), followed by
immunoblotting and qPCR to assess MMP-13 and
ADAMTS5 expression. Our results indicate that both
FGFR1 and FGFR3 were significantly knocked down on
their protein levels (Figure 2C). We did not observe any
off-target effects of these siRNA on the other FGFR iso-
forms (data not shown). Consistent with the results
acquired using FGFR inhibitors, FGFR1 knockdown
resulted in reversal of FGF-2-mediated up-regulation of
MMP-13 and ADAMTS5 (Figure 2A, B; P <0 . 0 5 ) .B y
stark contrast, FGFR3 knockdown did not significantly
modulate FGF-2-mediated MMP-13 or ADAMTS5
induction (Figure 2A, B), suggesting FGFR1 is the FGFR
isoform responsible for the catabolic actions of FGF-2 in
articular chondrocytes.
Coherent results were obtained in transient transfec-
tion studies that monitored integration of upstream
metabolic signals on the promoter of the MMP13 gene.
In previous studies, we showed that the first 1.6 kb of
the MMP-13 promoter (-1600 MMP-13 Luc reporter
construct) responded to FGF-2 stimulation by increasing
MMP-13 gene transcription [18]. Here we found that
FGF-2-induction of MMP-13 promoter-driven luciferase
activity was completely inhibited by SU5402 or neutra-
lizing FGFR1 antibody, with luciferase activity levels
returning to the control level (no treatment) (Figure
2D). These results further support our hypothesis that
FGFR1 is responsible for the FGF-2-induced MMP-13
expression in human articular chondrocytes.
Administration of FGF-2 significantly reduced the
expression of aggrecan (Figure 2E; P <0 . 0 5 ) ,am a j o r
component of proteoglycan in human articular chondro-
cytes. The inhibition of aggrecan expression by FGF-2
was completely reversed in the presence of either
SU5402 (5 µM), or neutralizing FGFR1 antibody in a
dose-dependent manner. Likewise, FGFR1 knockdown
abolished aggrecan down-regulation by FGF-2, whereas
FGFR3 knockdown failed to exert such an effect (Figure
2E; P < 0.05). Taken together, our results suggest that
pro-catabolic and anti-anabolic biological signals
mediated by FGF-2 are relayed through FGFR1 but not
FGFR3 in human adult articular chondrocytes.
FGFR1 and FGFR3 are predominantly expressed in normal
human adult articular chondrocytes
We examined the basal expression levels of FGFR family
members (FGFR1-4) at the cell surface to understand
which receptors mechanistically influence the biological
response to FGF-2 in human adult articular cartilage.
To determine expression levels of FGFRs, normal knee
chondrocytes (Collin’s grade 0 or 1, age group from 40
to 65) were subjected to flow cytometric analyses, using
anti-FGFR1 to four antibodies. Our results indicate that
FGFR3 and FGFR1 were the two most prominent recep-
tors at the cell surface of normal human articular chon-
drocytes (n=3) (Figure 3A). Similarly, cellular mRNA
and protein levels of FGFR3 and FGFR1 were predomi-
nantly higher than the levels of FGFR2 and FGFR4
based on RT-qPCR data (Figure 3B) and immunoblot-
ting analyses (Figure 3C). Compared with healthy chon-
drocytes, osteoarthritic chondrocytes did not up-regulate
FGFR2 or FGFR4 expression level (data not shown). We
also performed FGFR isoform expression analyses using
mRNA and protein acquired via different procedures
(that is, direct extraction from cartilage explants, extrac-
tion from cells immediately after enzymatic digestion,
and extraction from cells after up to five-day culture),
and we did not observe notable differences between
these methods regarding FGFR expression levels (data
not shown). These results collectively suggest that
FGFR3 and FGFR1 are the principal sensors of FGF
ligands in articular chondrocytes.
FGF-2 preferentially activates FGFR1, and to a lesser
extent, FGFR3 in human articular chondrocytes
FGF-2 signaling is initiated by ligand binding and subse-
quent activation of specific FGFRs. Because we observed
that FGFR1 and FGFR3 were predominantly expressed
in articular chondrocytes, we next asked a question:
Which type of FGFR(s) is activated in response to FGF-
2? We included FGF18 treatments in the experiments,
in parallel for comparison, as FGF18 exclusively acti-
vates FGFR3, in human adult articular chondrocytes.
Either FGF-2 or FGF18 (100 ng/mL) was administered
in serum-free media to human knee articular chondro-
cytes in monolayer. Immunoprecipitation (IP) analyses
were performed using either FGFR1 or FGFR3 antibody,
followed by immunoblotting with a phospho-Tyr (PY99)
antibody. In our initial time-course studies, we observed
the strongest receptor activation reflected by increased
phospho-tyrosine levels within 5 minutes, followed by a
rapid decrease within 30 minutes after treatment with
FGF-2 or FGF18 (data not shown). Therefore, we
selected the five-minute time point to determine specific
FGFR activation in response to FGF-2. Our IP results
s u g g e s tt h a tF G F - 2a c t i v a t e db o t hF G F R 1a n dF G F R 3
with a modest preference towards FGFR1 over FGFR3
in knee articular chondrocytes (Figure 4A). However,
FGF18 exclusively activated FGFR3 without detectable
activation of FGFR1 (Figure 4B). These results suggest
that selective FGFR-ligand interactions drive distinctive
signaling pathways and result in differential biological
outcomes in human adult articular chondrocytes.
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growth factors
FGFR3 has been shown to elicit anabolic responses in
cartilage (for example, FGF18), and Fgfr3-knockout mice
exhibit premature cartilage degradation and arthritis
[34,37]. Previously, we reported hyper-sensitization of
osteoarthritic cells to FGF-2 compared to normal chon-
drocytes [18]. We postulated that the functional differ-
ences in the FGF-2 response that are evident between
normal and OA cells, or between knee and ankle
(unpublished data) is related to altered levels of FGFR
subtypes in osteoarthritic chondrocytes. We investigated
this hypothesis by comparing FGFR1 and FGFR3 expres-
sion at both mRNA and protein levels in normal and
osteoarthritic chondrocytes. To minimize biological
variability in each group, the specimens were carefully
matched for age and gender. Results from RT-qPCR and
immunoblot analyses reveal a significant down-regula-
tion of FGFR3 in osteoarthritic cells at both mRNA
(Figure 5A; P < 0.05) and protein levels (Figure 5B)
when compared to normal cells. To understand changes
in the relative abundance of FGFR1 and FGFR3 in nor-
mal and osteoarthritic specimens, we simultaneously
quantified the mRNA levels of FGFR1 and FGFR3 in
each donor, and calculated the expression ratios of
FGFR1 to FGFR3. The data show that expression ratio
of FGFR1 to FGFR3 was significantly increased in OA
compared to normal chondrocytes (P < 0.05) (Figure
5C). In addition, no apparent correlation between donor
age and FGFR expression level was observed (data not
shown). Thus, imbalanced FGFR signaling may account
for the altered cellular responses to FGF-2 and FGF18
in the osteoarthritic state.
Because progression of OA depends on external sig-
naling ligands (for example, FGFs and BMPs), we inves-
tigated whether FGFR3 expression is down-regulated by
such factors in chondrocytes. Importantly, administra-
tion of FGF-2 significantly decreased the expression
level of FGFR3 (Figure 5D; P < 0.05). By contrast, BMP-
7, a well-known anabolic growth factor in cartilage,
Figure 3 Abundant FGFR1 and FGFR3 expression in articular chondrocytes. (A) Human articular chondrocytes were incubated with anti-
CD32/CD16 monoclonal antibody to block nonspecific antibody binding. FGFR1, FGFR2, FGFR3, and FGFR4 antibodies were incubated with cells,
followed by incubation with a secondary antibody, goat-anti-rabbit Alexa Fluor 488. Cells were also incubated with goat-anti-rabbit Alexa 488, or
non-immune rabbit serum plus goat-anti-rabbit Alexa Fluor 488 as controls. FGFRs on the plasma membrane of chondrocytes were analyzed
with a FACS Calibur instrument and CellQuest software. (B) Human articular chondrocytes in monolayer were subjected to RNA extraction, cDNA
synthesis, and qPCR quantification of FGFR isoform expression. * P < 0.05. (C) Human articular chondrocytes in monolayer were directly lysed.
Equal amounts of total protein were resolved on a SDS-PAGE gel, followed by transfer and immunoblotting of FGFR isoforms. FGF, fibroblast
growth factor; FGFR, FGF receptor; qPCR, quantative polymerase chain reaction.
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0.001) whereas the level of FGFR1 was not significantly
modulated in the presence of BMP-7 in human articular
chondrocytes. The suppression of FGFR3 expression by
FGF-2 was completely abolished in the presence of
either FGFR1 inhibitor or FGFR1 neutralizing antibody.
Similarly, knockdown of FGFR1 by siRNA rescued
FGFR3 suppression in the presence of FGF-2 (Figure
5D; P < 0.05). Furthermore, the inhibitor of the ERK
MAPK pathway significantly reversed FGF-2-mediated
reduction of FGFR3, suggesting that FGF-2-suppression
of FGFR3 is via FGFR1-ERK/MAPK axis in human
articular chondrocytes (Figure 5D).
Discussion
The balance between FGFR1 and FGFR3 signaling, and
the cognate ligands FGF-2 and FGF18, appears to be
vital for normal cartilage homeostasis [9]. While FGF-2
binds to all FGFR isoforms in vitro, it has greater affinity
for FGFR1 and FGFR3 [32]. The anabolic growth factor
FGF18 appears to act selectively through FGFR3 to acti-
vate distinct downstream pathways in human articular
chondrocytes. Of the four receptors for FGFs, we found
that FGFR1 and FGFR3 were predominantly expressed
in human adult articular chondrocytes. To assess the
specific roles of FGFR1 versus FGFR3, we used several
different experimental criteria. We applied multiple
approaches: two inhibitors with distinct modes of action
(that is, a chemical inhibitor that blocks the tyrosine
kinase activity of FGFR1 and an antibody directed
against FGFR1), specific siRNAs that target FGFR1 or
FGFR3, as well as comparisons between FGF-2 versus
FGF-18 treatments. Published data and our own empiri-
cal findings indicate that the chemical inhibitor, the
antibody, and the siRNA for FGFR1 each selectively tar-
get FGFR1, while FGF-2 and FGF-18 have different
downstream effects. These criteria together permit inter-
pretations that the primary functions of FGFR1 and
FGFR3 signaling by FGF-2 are distinctive in human
adult articular chondrocytes. While contributing func-
tions of FGFR3 in mediating FGF-2 signaling cannot be
ruled out categorically, our biological results favor the
interpretation that sustained FGF-2/FGFR1 signaling,
but not FGFR3 signaling, is primarily responsible for
proliferation, pro-catabolism as well as anti-anabolism in
adult human articular chondrocytes.
Absence of signaling from FGFR3 was demonstrated
to result in increased MMP-13 expression and cartilage
degradation, which resembles the osteoarthritic features
observed in mice overexpressing MMP-13 [37,38]. This
increase in MMP-13 may be due to elevated FGF-2 sig-
naling through FGFR1, which is a dominant, major
FGFR subtype in the absence of FGFR3 [33]. The orche-
strated and fine-tuned activities of FGFR1 and FGFR3
seem to be essential to extracellular matrix turnover
under normal condition [39]. The results presented in
this study collectively suggest that FGFR1 and FGFR3
promote catabolism and anabolism, respectively.
Arthritic tissues from OA patients exhibited substan-
tially decreased expression of FGFR3, thus possibly
intensifying FGFR1 signaling in human primary knee
joint articular chondrocytes. We also found that FGF-2/
Figure 4 Activation of FGFR1 and FGFR3 by FGF-2. (A) Human articular chondrocytes in monolayer were stimulated with FGF-2 (100 ng/mL)
for five minutes before whole cell lysates were prepared. The lysates were incubated with antibody against FGFR1 or FGFR3 in separate tubes.
Equal amounts of total protein after immunoprecipitation (IP) were resolved on SDS-PAGE gel, followed by immunoblotting of phospho-tyrosine.
Antibody against total FGFR1 or FGFR3 was used to evaluate loading precision. (B) Human articular chondrocytes in monolayer were stimulated
with FGF18 (100 ng/mL) for five minutes before whole cell lysates were prepared. The following steps were performed as described above. FGF,
fibroblast growth factor; FGFR, FGF receptor.
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articular chondrocytes. The observation that FGF-2
levels are abnormally elevated in synovial fluid of OA
patients fits a molecular model [18], in which FGF-2
initiates a self-reinforcing feedback loop that perpetuates
the characteristic degeneration of cartilage in OA, via
promoting FGF-2/FGFR1 signaling and simultaneously,
suppressing FGFR3-related pathways (for example,
FGFR3/FGF18 signaling). We o b s e r v e dd i s t i n c tc e l l u l a r
responses to FGF-2 in different biological contexts (for
example, between knee and ankle; normal and OA;
young and old, and so on). For example, we consistently
observed a more adverse effect of FGF-2 in aged tissue
donors ( > 45 years old) with damaged femoral regions
Figure 5 FGFR expression profiles and FGFR3 regulation in articular chondrocytes. (A) Age-matched, normal and osteoarthritic human
articular chondrocytes in monolayer were subjected to RNA extraction, cDNA synthesis, and qPCR quantification of FGFR3 expression. (B) Age-
matched, normal and osteoarthritic human articular chondrocytes were directly lysed for immunoblotting analyses of FGFR3. (C) Age-matched,
normal and osteoarthritic chondrocytes were subjected to RNA extraction, cDNA synthesis, and qPCR quantification of FGFR1 and FGFR3
expression. The FGFR1 to FGFR3 expression ratio was calculated in each donor. (D) Human articular chondrocytes in monolayer were pre-
incubated with SU5402 (5 μM) or PD98059 (ERK inhibitor, 50 μM) for 1 hour, and then treated with FGF-2 (100 ng/mL) for 24 hours. In parallel,
chondrocytes were transfected with siRNA targeting FGFR1 or FGFR3, and then stimulated by FGF-2 (100 ng/mL) for 24 hours. Total RNA was
extracted afterwards for cDNA synthesis and qPCR analyses of FGFR3 expression. * P < 0.05. (E) Human articular chondrocytes in monolayer were
administered with BMP7 (100 ng/mL) and cultured for 24 hours. Total RNA was extracted afterwards for cDNA synthesis and qPCR analyses of
FGFR1 and FGFR3 expression. ERK, extracellular signal-regulated kinase; FGF, fibroblast growth factor; FGFR, FGF receptor; qPCR, quantative
polymerase chain reaction.
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lished [19]. Nevertheless, we do not always observe the
same biological effects by FGF-2 using donor tissues
from young and normal knee cartilage with Collin’s
g r a d e0o ra n k l et i s s u e s .I np articular, although our IP
results suggest that FGF-2 more potently activates
FGFR1 than FGFR3 in knee articular chondrocytes, we
observed differential activities of FGFR1 and FGFR3 in
ankle chondrocytes after FGF-2 stimulation, in which
FGF-2-induced activation of FGFR3 was as potent as
FGFR1 (data not shown). We found these results very
interesting as it may provide a molecular mechanistic
understanding explaining, in part, why knee joints are
more vulnerable to OA compared with ankles. Our data
remain more consistent with the initial publications that
FGF-2 stimulates catabolism and/or anti-anabolism by
inducing cartilage degrading enzymes (for example,
MMP1, MMP13) and proteoglycan loss in articular car-
tilage in vitro and ex vivo [11,18,19]. However, we are
aware of some animal studies that demonstrated that
FGF-2-mediates anabolism in knee joints [40]. Although
these apparent discrepancies in biological effects are not
clearly understood yet, it may result from: age- and
grade-dependent differences (correlates with degree of
damage) between animal (young and healthy grade 0)
and human tissues ( > 45 years old, grade 0/1) or per-
haps, disease stage-specific expression/activation pattern
of FGF receptors (for example, FGFR1 versus FGFR3) as
we have shown in this study.
The findings presented here indicate that FGF-2 signal-
ing via FGFR1 is required for expression and/or tran-
scriptional regulation of the collagenase MMP-13 and
aggrecanase ADAMTS5, as well as suppression of the key
anabolic gene aggrecan. Cartilage degradation is linked to
ADAMTS5, and specific inhibition of ADAMTS5 is
chondroprotective for articular joints [41,42]. Interest-
ingly, we did not observe a significant induction of
ADAMTS4 upon FGF-2 stimulation. This finding sug-
gests that ADAMTS5 is preferentially modulated by
FGF-2 and may have a selective patho-physiological func-
tion that complements MMP-13 and other proteolytic
enzymes in OA. Aggrecan turnover occurs in healthy car-
tilage, and the imbalance between its production and
degradation results in defective extracellular matrix [39].
The repression of aggrecan by FGF-2-FGFR1 possibly
disrupts normal extracellular matrix metabolism and
facilitates further pathogenic progression.
The activation of chondrocyte proliferation by FGF-2/
FGFR1 activation observed in this study is consistent
with studies in various cell types, including chondrocytic
cells [43]. The effect of FGF-2 on stimulating chondro-
cyte proliferation and proteoglycan-degrading enzymes,
and reducing proteoglycan production, may compromise
the integrity of the extracellular matrix surrounding
newly divided chondrocytes. We previously reported
that the endogenous level of FGF-2 is highly increased
in osteoarthritic synovial fluids [18]. Increased chondro-
cyte proliferation was also observed in certain osteoar-
thritic populations [44]. Therefore, pathologically
elevated levels of FGF-2 in osteoarthritic synovial fluid
may influence not only cartilage but also the “whole
joint organ”, including synovial lining and subchondral
bone, which may promote fibroblastic proliferation of
chondrocytes, resulting in the formation of fibrocartilage
with altered biological and biomechanical properties. In
addition, neural ingrowth and angiogenesis in synovium,
which have been shown in the OA animal model and
patients with painful knee joint OA, may be directly
and/or indirectly promoted by FGF-2 [45].
Previously, we have shown that FGF-2 potently abro-
gated BMP-7-mediated proteoglycan synthesis and accu-
mulation [5,46]. Our current study demonstrates that
administration of FGF-2 suppressed the FGFR3 gene via
the activation of ERK/MAPK in human articular chon-
drocytes. Interestingly, we found that BMP-7 markedly
up-regulated FGFR3 expression, and this induction was
effectively blocked by the FGF-2-ERK/MAPK axis
(unpublished data). It is possible that BMP-7 augments
its anabolic activity, in part, via induction of FGFR3,
thus indirectly potentiating endogenous FGF18-FGFR3
signaling. This may explain the additive effect (if not
synergistic) of BMP-7 plus FGF18 on proteoglycan pro-
duction observed in another set of our studies in human
articular chondrocytes (unpublished data). One plausible
mechanism is that FGF-2 overrides stimulatory effects
of BMP-7 on FGFR3 expression, which negates the
responsiveness to FGF18 and diminishes proteoglycan
production. These speculations need to be confirmed by
a set of experiments in future studies.
Conclusions
In conclusion, we have provided evidence that FGFR1
primarily transmits detrimental signals in adult human
articular chondrocytes upon FGF-2 stimulation, as
opposed to FGFR3. FGFR1 signaling leads to inhibition
of proteoglycan accumulation, increased catabolic gene
expression, and decreased anabolic gene expression.
FGFR1 and FGFR3, which represent receptors with the
highest affinity for FGF-2, are dominantly expressed in
articular chondrocytes. FGFR1 is preferentially activated
by FGF-2 over FGFR3, which corroborates the catabolic
role of FGF-2. FGFR3 is significantly down regulated in
osteoarthritic chondrocytes, and the FGFR1 to FGFR3
expression ratio is elevated in OA. In addition, FGFR3 is
down-regulated by FGF-2 signaling through FGFR1-ERK
axis. Our findings suggest that FGFR1 specifically has a
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degeneration and OA pathophysiology.
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